Cytodyn Inc (CYDY)

[stockorus]

Questions sent to IR

Quote

In the 8-k, there were two charts that were confusing and concerning.

For the cancer trial, we are getting better data for patients having < 50% CCR5 expression. But don’t we expect our drug to stand out more in helping those with higher CCR5?

Secondly, in the LH data chart for CCL5/RANTES, the placebo is showing lower levels of RANTES. Shouldn’t LL treated patients have lesser RANTES since the drug blocks CCR5 and hence does not attract RANTES into lungs etc.?

Can you explain?

Unquote

I wish they had done these labs on cd12 or eINDs where cytokine storm is the main issue. Still this is a bit discomforting. Wonder if management can give a viable explanation; the entire premise of LL is that it is CCR5 antagonist.